189 related articles for article (PubMed ID: 30101858)
21. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
[TBL] [Abstract][Full Text] [Related]
22. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy.
Coppini R; Santini L; Olivotto I; Ackerman MJ; Cerbai E
Cardiovasc Res; 2020 Jul; 116(9):1585-1599. PubMed ID: 32365196
[TBL] [Abstract][Full Text] [Related]
23. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
24. Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome.
Liang P; Sallam K; Wu H; Li Y; Itzhaki I; Garg P; Zhang Y; Vermglinchan V; Lan F; Gu M; Gong T; Zhuge Y; He C; Ebert AD; Sanchez-Freire V; Churko J; Hu S; Sharma A; Lam CK; Scheinman MM; Bers DM; Wu JC
J Am Coll Cardiol; 2016 Nov; 68(19):2086-2096. PubMed ID: 27810048
[TBL] [Abstract][Full Text] [Related]
25. Deficiency of Transcription Factor Sp1 Contributes to Hypertrophic Cardiomyopathy.
Zhang F; Zhou H; Xue J; Zhang Y; Zhou L; Leng J; Fang G; Liu Y; Wang Y; Liu H; Wu Y; Qi L; Duan R; He X; Wang Y; Liu Y; Li L; Yang J; Liang D; Chen YH
Circ Res; 2024 Feb; 134(3):290-306. PubMed ID: 38197258
[TBL] [Abstract][Full Text] [Related]
26. Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits.
Smith JGW; Owen T; Bhagwan JR; Mosqueira D; Scott E; Mannhardt I; Patel A; Barriales-Villa R; Monserrat L; Hansen A; Eschenhagen T; Harding SE; Marston S; Denning C
Stem Cell Reports; 2018 Nov; 11(5):1226-1243. PubMed ID: 30392975
[TBL] [Abstract][Full Text] [Related]
27. iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy.
Escribá R; Larrañaga-Moreira JM; Richaud-Patin Y; Pourchet L; Lazis I; Jiménez-Delgado S; Morillas-García A; Ortiz-Genga M; Ochoa JP; Carreras D; Pérez GJ; de la Pompa JL; Brugada R; Monserrat L; Barriales-Villa R; Raya A
Circ Res; 2023 Jul; 133(2):108-119. PubMed ID: 37317833
[TBL] [Abstract][Full Text] [Related]
28. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.
Lan F; Lee AS; Liang P; Sanchez-Freire V; Nguyen PK; Wang L; Han L; Yen M; Wang Y; Sun N; Abilez OJ; Hu S; Ebert AD; Navarrete EG; Simmons CS; Wheeler M; Pruitt B; Lewis R; Yamaguchi Y; Ashley EA; Bers DM; Robbins RC; Longaker MT; Wu JC
Cell Stem Cell; 2013 Jan; 12(1):101-13. PubMed ID: 23290139
[TBL] [Abstract][Full Text] [Related]
29. CRISPR correction of the PRKAG2 gene mutation in the patient's induced pluripotent stem cell-derived cardiomyocytes eliminates electrophysiological and structural abnormalities.
Ben Jehuda R; Eisen B; Shemer Y; Mekies LN; Szantai A; Reiter I; Cui H; Guan K; Haron-Khun S; Freimark D; Sperling SR; Gherghiceanu M; Arad M; Binah O
Heart Rhythm; 2018 Feb; 15(2):267-276. PubMed ID: 28917552
[TBL] [Abstract][Full Text] [Related]
30. Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy.
Hanses U; Kleinsorge M; Roos L; Yigit G; Li Y; Barbarics B; El-Battrawy I; Lan H; Tiburcy M; Hindmarsh R; Lenz C; Salinas G; Diecke S; Müller C; Adham I; Altmüller J; Nürnberg P; Paul T; Zimmermann WH; Hasenfuss G; Wollnik B; Cyganek L
Circulation; 2020 Sep; 142(11):1059-1076. PubMed ID: 32623905
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes.
Shiba M; Higo S; Kondo T; Li J; Liu L; Ikeda Y; Kohama Y; Kameda S; Tabata T; Inoue H; Nakamura S; Takeda M; Ito E; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
Hum Mol Genet; 2021 Jul; 30(15):1384-1397. PubMed ID: 33949662
[TBL] [Abstract][Full Text] [Related]
32. Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review.
Eschenhagen T; Carrier L
Pflugers Arch; 2019 May; 471(5):755-768. PubMed ID: 30324321
[TBL] [Abstract][Full Text] [Related]
33. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease.
Chou SJ; Yu WC; Chang YL; Chen WY; Chang WC; Chien Y; Yen JC; Liu YY; Chen SJ; Wang CY; Chen YH; Niu DM; Lin SJ; Chen JW; Chiou SH; Leu HB
Int J Cardiol; 2017 Apr; 232():255-263. PubMed ID: 28082092
[TBL] [Abstract][Full Text] [Related]
34. Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes.
Josowitz R; Mulero-Navarro S; Rodriguez NA; Falce C; Cohen N; Ullian EM; Weiss LA; Rauen KA; Sobie EA; Gelb BD
Stem Cell Reports; 2016 Sep; 7(3):355-369. PubMed ID: 27569062
[TBL] [Abstract][Full Text] [Related]
35. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
36. Development of induced pluripotent stem cells from a patient with hypertrophic cardiomyopathy who carries the pathogenic myosin heavy chain 7 mutation p.Arg403Gln.
Holliday M; Ross SB; Lim S; Mangala M; Hill A; Szappanos HC; Hool L; Semsarian C
Stem Cell Res; 2018 Dec; 33():269-273. PubMed ID: 30508693
[TBL] [Abstract][Full Text] [Related]
37. An insight of novel pharmacological therapies in hypertrophic cardiomyopathy.
Orenes-Piñero E; Hernández-Romero D; Jover E; de la Morena G; Valdés M; Marín F
Med Chem; 2011 Jul; 7(4):275-85. PubMed ID: 21568880
[TBL] [Abstract][Full Text] [Related]
38. 1-Deoxynojirimycin promotes cardiac function and rescues mitochondrial cristae in mitochondrial hypertrophic cardiomyopathy.
Zhuang Q; Guo F; Fu L; Dong Y; Xie S; Ding X; Hu S; Zhou XD; Jiang Y; Zhou H; Qiu Y; Lei Z; Li M; Cai H; Fan M; Sang L; Fu Y; Zhang D; Lin A; Li X; Kunath T; Zhou R; Liang P; Liu Z; Yan Q
J Clin Invest; 2023 Jul; 133(14):. PubMed ID: 37200096
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic Analysis of Cardiomyocyte Extracellular Vesicles in Hypertrophic Cardiomyopathy Reveals Differential snoRNA Cargo.
James V; Nizamudeen ZA; Lea D; Dottorini T; Holmes TL; Johnson BB; Arkill KP; Denning C; Smith JGW
Stem Cells Dev; 2021 Dec; 30(24):1215-1227. PubMed ID: 34806414
[TBL] [Abstract][Full Text] [Related]
40. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.
Raval KK; Tao R; White BE; De Lange WJ; Koonce CH; Yu J; Kishnani PS; Thomson JA; Mosher DF; Ralphe JC; Kamp TJ
J Biol Chem; 2015 Jan; 290(5):3121-36. PubMed ID: 25488666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
